Table of Content


Chapter 1 Introduction
Introduction
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Analyst’s Credentials
Chapter 2 Introduction to COVID-19
Overview of Pandemic Outbreaks
History of Outbreak
Symptoms of COVID-19
Progression of COVID-19
Incubation Period
Epidemiology
Case-Fatality Rate (CFR)
Global Confirmed Cases and Confirmed Deaths Due to COVID-19
Lessons Learned from the Past
Healthcare Worker Infections
Collaboration Between Organizations and Governments
Spread of the Disease
Chapter 3 COVID-19 and R&D Efforts
Potential Targets for COVID-19 Drug Development
Basigin (CD147)
C-C Chemokine Receptor Type 5 (CCR5)
Envelope Protein (E) (SARS-CoV-2; COVID-19 Virus)
Epithelial Sodium Channel (ENaC)
Histamine N-Methyltransferase (HMT)
Interleukin-6 Receptor Subunit ? (IL-6RA)
Membrane Glycoprotein (M) (SARS-CoV-2; COVID-19)
Nucleocapsid (N) (SARS-CoV-2; COVID-19)
Research and Development on COVID-19
Diagnostics and Medtech
The Need to Reinvent Ventilators
COVID-19 Clinical Trial Landscape
Chapter 4 Economic Impact of COVID-19
Impact of Coronavirus on the Global Economy
Government Expenditures on COVID-19
Predictions on the Global Economy
Quick Recovery
Global Slowdown
Pandemic and Recession
Social Impact of COVID-19
Chapter 5 Impact of COVID-19 on the Healthcare Industry
Impact of COVID-19 on Pharma Supply Chains
Disruption of Clinical Trials
Impact on Insurance Providers
Impact on Health Technology Assement
Threat to Healthcare Acquisitions
Chapter 6 Regulatory Scenario and COVID-19
Coronavirus Treatment Acceleration Program (CTAP)
Clinical Trials Being Conducted During the COVID-19 Pandemic
Drug Shortages Response
National Regulatory Agencies for Ongoing Clinical Trials During the COVID-19 Pandemic
U.S. FDA
Medicines and Healthcare Products Regulatory Agency (U.K.)
European Medicines Agency
Chapter 7 Future Implications
Public Health
Planning for the Economic Recovery
Short-Term Considerations
Long-Term Considerations



List of Figures


Figure 1 : Infographic Comparison of the CFRs of the Three Major Beta Coronaviruses: MERS, SARS and COVID-19
Figure 2 : Distribution of Clinical Trials on COVID-19, by Phase
Figure 3 : Distribution of Clinical Trials on COVID-19, by Intervention
Figure 4 : Distribution of Clinical Trials on COVID-19, by Country
Figure 5 : Comparison of GDP Growth, by Select Countries, 2019 and 2020
Figure 6 : Global Healthcare Performance, by Financial Times Stock Exchange (FTSE)
Figure 7 : Distribution of the Disruption of Clinical Trials Due to COVID-19, by Therapeutic Area

 

List of Tables


Table 1 : COVID-19 Symptoms, by Percentage of Patients
Table 2 : COVID-19 CFR, by Region, as of March 2020
Table 3 : COVID-19 CFR, by Selected Countries, as of March 2020
Table 4 : COVID-19 Confirmed Cases and Deaths, by Country, as of April 15, 2020
Table 5 : COVID-19 Cases and Deaths per 1 Million Population, by Selected Country
Table 6 : Total Number of Diagnostic Tests Performed per 1 Million Population, by Selected Country
Table 7 : COVID-19 Therapeutic Interventions in Development, by Biopharmaceutical Company Collaborations
Table 8 : COVID-19 Therapeutics in Development, by Biopharmaceutical Company
Table 9 : COVID-19 Vaccines in Development by Biopharmaceutical Companies in Collaboration
Table 10 : COVID-19 Vaccines in Development, by Biopharmaceutical Company
Table 11 : Modifiable Breathing Devices Eligible for Emergency Use Authorization (EUA), by Company
Table 12 : Clinical Trials on COVID-19, by Phase
Table 13 : Clinical Trials on COVID-19, by Intervention
Table 14 : Clinical Trials on COVID-19, by Country
Table 15 : Interim Economic Outlook Forecasts, as on 2 March 2020
Table 16 : Expenditures on COVID-19 Crisis
Table 17 : Disruptions of Clinical Trials Due to COVID-19, by Therapeutic Area
Table 18 : Selected Pending Acquisitions in the Healthcare Industry